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Abstract
Background: Patients with initially low visual acuity were excluded from the therapy approval studies for retinal
vein occlusion. But up to 28 % of patients presenting with central retinal vein occlusion have a baseline BCVA of
less than 34 ETDRS letters (0.1). The purpose of our study was to assess visual acuity and central retinal thickness in
patients suffering from central retinal vein occlusion and low visual acuity (<0.1) in comparison to patients with
visual acuity (≥0.1) treated with Dexamethasone implant 0.7 mg for macular edema.
Methods: Retrospective, controlled observational case study of 30 eyes with macular edema secondary to central
retinal vein occlusion, which were treated with a dexamethasone implantation. Visual acuity, central retinal
thickness and intraocular pressure were measured monthly. Analyses were performed separately for eyes with visual
acuity <0.1 and ≥0.1.
Results: Two months post intervention, visual acuity improved only marginally from 0.05 to 0.07 (1 month; p = 0,065)
and to 0.08 (2 months; p = 0,2) in patients with low visual acuity as compared to patients with visual acuity ≥0.1 with
an improvement from 0.33 to 0.47 (1 month; p = 0,005) and to 0.49 (2 months; p = 0,003). The central retinal thickness,
however, was reduced in both groups, falling from 694 to 344 μm (1 month; p = 0.003,) to 361 μm (2 months;
p = 0,002) and to 415 μm (3 months; p = 0,004) in the low visual acuity group and from 634 to 315 μm (1 month;
p < 0,001) and to 343 μm (2 months; p = 0,001) in the visual acuity group ≥0.1. Absence of visual acuity improvement
was related to macular ischemia.
Conclusions: In patients with central retinal vein occlusion and initially low visual acuity, a dexamethasone
implantation can lead to an important reduction of central retinal thickness but may be of limited use to increase
visual acuity.
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Background
Retinal vein occlusions (RVO) are the most common pri-
mary vascular diseases of the retina [1, 2]. Branch retinal
vein occlusions (BRVO) are more common than central
retinal vein occlusions (CRVO) with a prevalence of 0.6–
1.1 versus 0.1–0.4 % in the general population [3, 4]. The
spontaneous disease course is often poor especially in
CRVO and hemi CRVO but also in BRVO. The majority
of patients with retinal vein occlusion suffer from visual
deterioration because of macular edema (ME). Quinlan [5]
found in 1990 that only 13 to 17 % of patients with CRVO
had a significant visual acuity (VA) gain without treatment.
The visual prognosis is thereby dependent on the initial
VA and the degree of retinal ischemia [6]. An initial
VA of <20/200 (<0.1) seems to be connected with a low
VA prognosis. During the natural course of CRVO
patients will suffer a medium VA impairment of 1 line VA
chart [6].
The sham injection groups of the newer RVO therapy
trials [7, 8] provide also data of the spontaneous disease
course. Patients of the CRVO sham group lost in average
1 to 2 letters after 6 months of follow up during the
GENEVA trial. In contrast to this the BRVO sham group
gained 5 letters in average after 6 months [7, 8]. The
GENEVA trial [7, 8] excluded RVO patients with a
BCVA of less than 34 ETDRS letters (0.1). But up to
28 % of patients presenting with CRVO have a baseline
BCVA of less than 34 ETDRS letters and more than
80 % have a poor final VA if untreated [6].
The CRVO study group found in 1995 that grid pattern
photocoagulation may reduce the leakage but without VA
gain in CRVO patients with ME [9]. Since the Dexametha-
sone implant Ozurdex® (DEX implant) and the VEGF in-
hibitors Ranibizumab and Aflibercept were approved by
the European Medicines Agency (EMA) in 2010, 2011
and 2013 for the treatment of ME secondary to RVO, the
therapeutic options improved. However it is not clear if
these new drugs have the capacity to improve the visual
prognosis of patients with initial low VA (<0.1). In this
study CRVO patients with low VA have been treated with
DEX implantation. The aim was to evaluate the outcome
after intervention in this specific patient population.
Methods
In this retrospective, controlled, observational case study
30 eyes of 29 patients with ME secondary to CRVO were
treated with a 700 μg sustained delivery, bioerodable
Dexamethasone intravitreal implant (DEX implant;
Ozurdex®; Allergan, Inc., Irvine, CA) between November
2010 and July 2011. All patients gave their informed con-
sent and all procedures were in concordance with the
tenets of the Declaration of Helsinki. All patients were
treated on label so that no ethics approval was needed for
the retrospective chart review.
Patients
Patients with ME >300 μm secondary to CRVO were in-
cluded into the study. Patients with known glaucoma
were only included in case of well controlled intraocular
pressure (IOP). Some patients received topical glaucoma
medication after the CRVO occured because neuropro-
tection is suspected for e.g. carbonic anhydrase inhibit-
ing eye drops [10, 11]. Exclusion criteria were any ocular
condition that was able to interfere with potential visual
improvement and a pre-treatment with a DEX implant-
ation at any time point. Analyses were performed separ-
ately for eyes with visual acuity <0.1 (15 eyes) and ≥0.1
(15 eyes).
Follow- up and treatment
The baseline examinations included assessment of VA and
IOP, complete ophthalmologic examination and central
retinal thickness (CRT) measured by Spectral Domain
Optical Coherence Tomography (SD-OCT) (Heidelberg
Eye Explorer Version 6.011.0, Heidelberg Spectralis,
Heidelberg Engineering, Heidelberg, Germany) before DEX
implantation. Follow-up was conducted every 4 weeks over
a time period of 6 months including VA, SD-OCT and
complete ophthalmologic examination. A retreatment was
performed mostly after 5 to 6 months if necessary so that
this report refers only till month 5 after DEX implantation.
Decimal visual acuity was converted into ETDRS letters
with a VA conversion chart [12] to compare our results
with the newer RVO therapy trials.
Side effects of the DEX implant were monitored by
measuring the IOP every 4 weeks. Fluorescein angiog-
raphy (FA) was performed in cases of missing contrain-
dications (renal failure, reduced general condition, dye
allergies) before DEX implantation or during the disease
course to visualise macular and retinal perfusion. The
FA procedure followed the multi-field protocol used by
the Central Vein Occlusion Study Group, with standard
5- view angiography [13] using the HRA Spectralis
(Heidelberg Eye Explorer Version 6.011.0, Heidelberg
Engineering, Heidelberg, Germany) with a 55° lens and
the patients were asked to look in all directions to
visualize the periphery. In cases of significant peripheral
retinal ischemia patients were treated with panretinal
photocoagulation to avoid neovascularisation and rubeotic
secondary glaucoma. The peripheral retina was regarded as
ischemic if ischemia amounted more than 10 disc diame-
ters. Retreatment with DEX implantation or Ranibizumab
was considered in cases of recurrent ME.
Statistics
Data were checked for normal distribution and results are
expressed in mean ± standard deviation (SD). Normally-
distributed variables were compared with a matched
paired sample t-test. Numeric variables that were not
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normally distributed were compared with the matched
paired Wilcoxon signed rank test. The Chi2- test was used
to compare the gender differences between the groups.
The results were regarded as statistically significant if p
was below 0.05. Statistics were performed with SPSS
(Version 21.0.0.0, IBM, United States).
Results
Patients
Low visual acuity group
Six men and nine women with a baseline visual
acuity <0.1 (15 eyes) were treated with a DEX implant-
ation. The mean time after CRVO was 9 (±6.9) months in
this group and the mean age of patients 72.5 (±9) years.
Four patients (26.7 %) were pretreated with bevacizumab.
Six patients (40 %) received topical glaucoma medication
to protect the optic nerve head. One patient was diag-
nosed with chronic open angle glaucoma.
Control group
The control group consisted of seven men and eight
women with a baseline visual acuity ≥0.1 (15 eyes) and a
mean time after CRVO of 9 (±7.3) months. The mean
age of the control group amounted 72.3 (±9.9) years.
Two patients (13.3 %) were pretreated with bevacizumab
and one patient (6.7 %) was pretreated with bevacizumab
and triamcinolone. Eight patients (53.3 %) received top-
ical glaucoma medication at baseline. Two of these pa-
tients were diagnosed with chronic open angle glaucoma
before treatment.
All DEX implantations were performed under stan-
dardized conditions (operating theatre, topical anaesthe-
sia, sterile conditions, DEX implantation in tunnel
technique in 3.5 mm distance of the limbus) without im-
plantation related complications.
Visual acuity
Low visual acuity group
Throughout the follow up the distance VA of the low
VA group improved compared to baseline (Table 1). VA
improvement showed a weak effect but without statis-
tical significance at any time point. The conversion into
ETDRS letters is seen in Table 1, Figs. 1 and 2. The
Additional file 1a-e shows in more detail the ETDRS
letter change compared to baseline during month 1 to 5
after DEX implantation. A ≥15 letter improvement was
achieved in 40 % of patients and a ≥10 letter improve-
ment in 53.3 % of patients at any time point.
Control group
In the control group, the distance VA assessment
showed an improvement at month 1 (p = 0.005) and
month 2 (p = 0.003) (Table 2). The conversion into
ETDRS letters is shown in Table 2, Figs. 1 and 2 with
the same effect from month 1 (p = 0.002) to month 2
(p = 0.013). The Additional file 2a-e shows in more
detail the ETDRS letter change compared to baseline
during month 1 to 5 after DEX implantation. A ≥15
letter improvement was achieved in 46.7 % of patients
and a ≥10 letter improvement in 73.3 % of patients at
any time point.
Central retinal thickness
Low visual acuity group
The CRT assessed by SD-OCT was reduced compared
to baseline with strong evidence for an effect during the
first (p = 0.003), second (p = 0.002) and third month
(P = 0.004) after DEX implantation (Table 1).
Control group
In the control group the CRT was reduced compared to
baseline again with a strong evidence for an effect from
month 1 (p < 0.001) to month 2 (p = 0.001) (Table 2).
Fluorescein angiography and panretinal
photocoagulation
FA was performed in 14 eyes of the low VA group and
11 eyes of the control group before (18 eyes) or after
DEX implantation (seven eyes). The remaining five pa-
tients did not receive a FA because of contraindications.
Low visual acuity group
FA showed macular ischemia in 64.3 % of patients
(Table 3, Fig. 3) shows a case report). Peripheral retinal
ischemia was present in 84.6 % of patients during FA like-
wise (Table 3, Fig. 3). One of the patients with macular is-
chemia did not have peripheral retinal ischemia and three
other patients with perfused macular showed peripheral
retinal ischemia. In total 57.1 % of patients showed macu-
lar and peripheral retinal ischemia at the same time point.
The periphery of one patient could not be evaluated
Table 1 VA and CRT in 15 CRVO patients with baseline VA <0.1
Visual acuity ETDRS letters (VA) CRT (μm)
Baseline (±SD) 0.05 (±0.03) 20 (±12) 694 (±301)
1 mo follow-up 0.07 (±0.05) 28 (±13) 344 (±127)
P-value 0.065 0.1 0.003*
2 mo follow-up 0.08 (±0.04) 23 (±14) 361 (±226)
P-value 0.2 0.23 0.002*
3 mo fyollow-up 0.07 (±0.04) 24 (±13) 415 (±224)
P-value 0.14 0.19 0.004*
4 mo follow-up 0.05 (±0.03) 17 (±12) 534 (±299)
P-value 0.31 0.8 0.094
5 mo follow-up 0.06 (±0.04) 20 (±12) 665 (±340)
P-value 0.93 0.82 0.14
(*p-values with statistical significance)
Winterhalter et al. BMC Ophthalmology  (2016) 16:187 Page 3 of 8
because of poor quality. All patients received panretinal
photocoagulation (100 %).
Control group
Macular ischemia was present in 18.2 % of patients
(Table 3, 63.6 % perfused, 18.2 % not evaluable). Periph-
eral retinal ischemia could be detected in 36.4 % of pa-
tients (Table 3, 36.4 % perfused, 27.3 % not evaluable).
Only one patient showed macular and peripheral retinal
ischemia at the same time point. Eight patients were
treated with panretinal photocoagulation (53.3 %).
Intraocular pressure (IOP)
Low visual acuity group
The median IOP was: 14.3 ± 2.4 mmHg (baseline);
18.5 ± 2.6 mmHg (month 1); 19.3 ± 4 mmHg (month 2);
17.1 ± 1.6 mmHg (month 3); 16.7 ± 3 mmHg (month 4)
and 17.8 ± 9.9 mmHg (month 5). The IOP lowering
medication had to be intensified in one patient with open
angle glaucoma and in three further patients (26.7 %).
Control group
In this group the median IOP was: 14.1 ± 5.2 mmHg
(baseline); 18.9 ± 8.2 mmHg (month 1); 19.1 ± 7.4 mmHg
(month 2); 16.8 ± 3.5 mmHg (month 3); 16.4 ± 4 mmHg
(month 4) and 13 ± 2.6 mmHg (month 5). One patient
with open angle glaucoma and 5 further patients needed
an intensified IOP lowering medication (40 %).
The IOP raised to ≥25 mmHg in 20 % of patients and
a ≥10 mmHg increase of IOP from baseline at 60 days
was seen in 13.3 % of patients. Three patients suffered
of IOP decompensation with 40 mmHg in month 1
control group low VA group









baseline 1 mo 2 mo 3 mo 5 mo
low visual acuity group
control group
GENEVA trial
Fig. 2 Mean BCVA improvement in numbers of letters of the low visual acuity and control group in comparison to the GENEVA trial
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(control group) and 38 mmHg in month 2 (control
group) after DEX implantation. One patient with an in-
traocular pressure of 35 mmHg in month 5 showed
rubeotic secondary glaucoma (low VA group) and was
treated with retinal cryocoagulation during follow-up.
Retreatment
A retreatment was performed in 6 patients (40 %) of the
low visual acuity group 4 to 9 months after DEX im-
plantation with a medium retreatment time of 7 months.
Patients of the control group were retreated in 53.3 %
(8 patients) 5 to 8 months after DEX implantation with
a medium retreatment time of 5.9 months.
Discussion
Our retrospective controlled study was performed to
evaluate VA gain after DEX implantation in patients with
initially low VA <0.1 because CRVO is often related to
limited visual prognosis [5, 6, 14] and the GENEVA trial
[7, 8] excluded RVO patients with a BCVA of less than
34 ETDRS letters (0.1). Our results show that patients
with initially low VA can profit of DEX implantation
despite weak evidence for an effect: 40 % of patients
achieved a ≥15 letter improvement and 53.3 % of pa-
tients a ≥10 letter improvement at any time point.
In contrast patients of the control group experienced
VA amelioration with strong evidence for an effect from
month 1 (p = 0.005) to month 2 (p = 0.003). This is in
concordance to other studies [15, 16]. The ETDRS letter
gain of the control group was higher than in the low VA
group with 46.7 % of patients who gained ≥15 letters and
73.3 % of patients who improved with ≥10 letters at any
time point. During the GENEVA trial [7, 8] a ≥15 letter
improvement in BCVA from baseline was seen in up to
30 % in the 0.7 mg DEX group and at least a ≥10 letter
improvement in up to 55 % of eyes.
In opposition to our results Dinah [17] described in 19
CRVO patients with a baseline BCVA of less than 34
ETDRS letters that 70 % of patients gained ≥15 letters.
In their study, up to a third of patients achieved a BCVA
of 55 ETDRS letters after DEX implantation. In our
study no patient of the low VA group achieved 55
ETDRS letters and only 1 patient achieved 45 ETDRS
letters and another one 40 ETDRS letters.
The limited VA gain in our low VA group was related
to macular ischemia which amounted up to 64.3 %.
In clinical experience macular ischemia is often not
visible during FA in cases of diffuse edema. After ME
resolution, the ischemia becomes apparent in FA. In
contrast to the low VA group macular ischemia was
present in 18.2 % in the control group. A high correl-
ation is known between low baseline VA and presence
or development of ischemia [6]. Therefore, the benefit of
patients with low VA and macular ischemia seems to be
limited after DEX implantation. As Dinah et al. [17] did
not evaluate FA, the retinal perfusion status of the co-
hort is not known.
Another recent study of Parodi examined DEX im-
plants for macular edema secondary to ischemic retinal
vein occlusions [18]. Fifteen patients with CRVO and
macular and retinal ischemia were included in this study
with a follow up of 12 months. The median ETDRS let-
ter score of these patients was 10 at baseline. This is in
contrast to our case series of 15 patients with low VA
with a median ETDRS letter score of 20 at baseline. The
CRVO patients of Parodis group gained 10 ETDRS
letters after 1 month which is comparable with a letter
gain of 8 ETDRS letters after 1 month in our patients.
But in contrast to our patients, who worsened again at
month 2, Parodis CRVO patients showed a steady letter
gain till 37 ETDRS letters (0.1) at 12 months, which
might be relevant for the patient but is limited too,
through a mean number of 2.8 DEX implantations. All
15 patients of Parodis study were diagnosed with macu-
lar and retinal ischemia, which was the inclusion criter-
ion. The inclusion criterion of our patients was a VA
<0.1 to evaluate VA expectations in low VA patients be-
cause no informations are available of the approval studies
for these patients. Parodis CRVO patients showed a CRT
reduction from 749 μm at baseline to 363 μm at the
12 month examination. This is comparable to our patients
with a CRT reduction from 694 μm to the minimum CRT
of 344 μm on month 1 after DEX implantation. A reevalu-
ation of the perfusion status of Parodis patients would
Table 2 VA ad CRT in 15 CRVO patients with baseline VA ≥ 0.1
Visual acuity ETDRS letters (VA) CRT (μm)
Baseline (±SD) 0.33 (±0.27) 55 (±17) 634.38 (±130.40)
1 mo follow-up 0.47 (±0.27) 65 (±13) 314.92 (±77.88)
P-value 0.005* 0.002* <0.001*
2 mo follow-up 0.49 (±0.29) 65 (±25) 343.27 (±73.89)
P-value 0.003* 0.013* 0.001*
3 mo follow-up 0.44 (±0.37) 56 (±25) 483.17 (±255.16)
P-value 0.24 1 0.18
4 mo follow-up 0.4 (±0.35) 55 (±24) 534.13 (±191.86)
P-value 0.49 0.97 0.24
5 mo follow-up 0.39 (±0.39) 54 (±26) 490.5 (±76.15)
P-value 0.13 0.77 0.23
(*p-values with statistical significance)
Table 3 Macular and peripheral retinal ischemia of the low VA
group in comparison to the control group
Ischemia visualized by FA Low VA group Control group
Macular 64.3 % 18.2 %
Peripheral retinal 84.6 % 36.4 %
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have been interesting because of the steady letter gain till
month 12. There are hints that aggressive blockade of
VEGF with ranibizumab prevents the worsening of retinal
non perfusion, promotes reperfusion and eliminates a
positive feedback loop in patients with RVO [19].
Our results are in concordance with the study of
Maggio [20] in which 21 eyes with CRVO, 20 eyes with
BRVO and two eyes with hemiretinal vein occlusion
(HRVO) were treated with a DEX implantation. They
found that only the nonischemic CRVO subgroup had a
statistically significant improvement in BCVA and CRT.
The ischemic CRVO group did not improve significantly
in BCVA in spite of significant improvements in CRT
[20]. The CRT of our low VA group was reduced as well
with strong evidence for an effect from month 1 to 3
(p = 0.003; p = 0.002; p = 0.004) despite a weak evidence
for an effect concerning BCVA improvement. Other
studies confirm that macular ischemia is a significant
negative factor for VA improvement as described for
intravitreal Bevacizumab for ME due to BRVO [21].
In our study the highest mean BCVA improvement in
numbers of letters was similar to the GENEVA trial but
our patients reached their highest letter gain earlier and
dropped down earlier than the patients of the GENEVA
trial. Effects of Dexamethasone implants are known in
the literature as early as 7 days after injection regarding
VA improvement and CRT reduction [22, 23]. Probably,
an earlier treatment and retreatment might have been
associated with a more favourable outcome.
Concerning the safety results a ≥10 mmHg increase of
IOP from baseline was seen in 13.3 % of patients com-
pared to 12.6 % of patients at day 60 of the GENEVA trial
[7, 8]. In total the topical glaucoma- medication had to be
intensified in 33.3 % of patients of our study whereas
25.5 % of patients began an IOP lowering medication dur-
ing the masked phase of the GENEVA trial [7, 8].
A combination therapy of vascular endothelial growth
factor (VEGF) inhibitors and DEX implants might have
been associated with better VA results because the
medium CRT was higher than 300 μm after DEX im-
plantation in both groups of our study at any time point.
Regarding the literature a combination therapy of vascu-
lar endothelial growth factor (VEGF) inhibitors and
DEX implants improved significantly the VA outcome in
BRVO patients but not in CRVO patients [24]. However,
the approval studies for VEGF inhibitors [25–27] to treat
ME due to RVO showed a higher ETDRS letter gain
than the GENEVA trial [7, 8]. A combination therapy
may lead to higher VA gain despite fewer necessary in-
jections than with VEGF inhibitor therapy alone [28–31]
and may be therefore cost-effective [32]. Despite this a
combination therapy would not resolve the macular and
retinal ischemia which was associated to limited final
VA in our study. Otherwise CRVO patients of the
CRYSTAL study with macular ischemia showed a VA
improvement of 11.6 ETDRS letters under 3 primary
Ranibizumab injections and following PRN treatment
after 12 months which was comparable to patients
a b
c
Fig. 3 a – c 81 year old lady, who suffered of CRVO with low VA on her left eye and was treated with a DEX implantation 2 months after the
occlusion. a VA counted 3 ETDRS letters at baseline with a CRT of 924 μm measured with the SD- OCT. b VA augmented to 35 ETDRS letters (0.1)
1 month after treatment with a reduced CRT of 214 μm. c VA gain was limited because the macula and retina were totally ischemic as seen in FA
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without macular ischemia (12.1 ETDRS letters) [33]. But
the inclusion criterion of the CRYSTAL study was a
baseline BCVA of 19 to 73 ETDRS letters (0.05–0.5)
whereas the inclusion criterion for our low VA group
was a VA <34 ETDRS letters (<0.1). So a more severe
macular ischemia is suspected in our patients than that
of the patients of the CRYSTAL study or Ranibizumab
might be more effective in CRVO patients with macular
ischemia than DEX implants.
Our study has a number of limitations. First, this was
a retrospective study, and therefore we do not have full
control over confounding factors. Also, our results have
to be interpreted with caution due to the small sample
size which resulted in low statistical power. Hence, inter-
pretation of our findings should consider observed
trends and not entirely rely on statistical significance.
These trends are largely similar to the trends bowered in
larger studies such as the GENEVA trial (Fig. 2) which
makes a chance finding unlikely. A further limitation re-
sults in the mean duration of CRVO which was 9 months
in the low VA group and could have resulted in a lower
VA gain. But it has to be said that the mean duration of
CRVO was 9 months in the control group as well which
showed a similar ETDRS letter gain than the patients of
the GENEVA trial. This study was performed shortly
after DEX implants were approved in Europe for the
treatment of RVO, so the duration of CRVO was longer
in some patients and some patients were pretreated with
bevacizumab. But the baseline characteristics of the con-
trol group were similar to the low VA group so that our
results seem to be realistic. Our results showed as well,
that some patients should have been retreated earlier as
described before [16], which was a learning effect.
Conclusion
VA prognosis is limited after DEX implantation in
CRVO patients with initial low VA because of macular
ischemia. Despite the limited VA prognosis we would
recommend to treat patients due to the fact that these
patients showed a slight benefit in our study. However,
patients should be informed about the limited VA prog-
nosis to avoid unrealizable expectations. The results may
help to prevent risks and burden for the patients and
costs for the health care system in patients with CRVO
and low VA.
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5 months after DEX implantation compared to baseline of the control
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